Novartis Financial Results - Q3 2026
Novartis announces the company’s financial results for the third quarter of 2026.
Novartis breaks ground on new RLT manufacturing site in Denton, Texas
Novartis' first Texas-based manufacturing facility expands US RLT production closer to patients across the southern US, becoming the fifth RLT site nationwide.
Discover our medicines
See how our innovative medicines are addressing society's greatest health challenges.
Commitment to patients
From research and development to expanding access, uncover our commitment to improving people's lives.
Inspired by purpose
Learn about our people and culture, and how we're driven by our mission to reimagine medicine.
Latest News
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
